Trial Profile
A randomised trial of thymoglobulin to prevent chronic graft versus host disease in patients undergoing haematopoietic progenitor cell transplantation (HPCT) from unrelated donors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Immunosuppressants
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 Mar 2010 New trial record